ANCHIANO THERAPEUTICS LTD. AND THE BANK OF NEW YORK MELLON As Depositary AND OWNERS AND HOLDERS OF AMERICAN DEPOSITARY SHARES Deposit Agreement Dated as of _______________, 2019Deposit Agreement • February 5th, 2019 • Anchiano Therapeutics Ltd. • Pharmaceutical preparations • New York
DEPOSIT AGREEMENT dated as of _________________, 2019 among ANCHIANO THERAPEUTICS LTD., a company incorporated under the laws of Israel (herein called the Company), THE BANK OF NEW YORK MELLON, a New York banking corporation (herein called the Depositary), and all Owners and Holders (each as hereinafter defined) from time to time of American Depositary Shares issued hereunder.
ANCHIANO THERAPEUTICS LTD. [____] American Depositary Shares Representing [____] Ordinary Shares UNDERWRITING AGREEMENTUnderwriting Agreement • February 5th, 2019 • Anchiano Therapeutics Ltd. • Pharmaceutical preparations • New York
Anchiano Therapeutics Ltd., a company organized under the laws of the State of Israel (the “Company”), proposes, subject to the terms and conditions contained herein, to sell to you and the other underwriters (the “Underwriters”) named on Schedule I to this Underwriting Agreement (the “Agreement”), for whom you are acting as Representative (the “Representative”), an aggregate of ________ American Depositary Shares (the “Firm Shares”), each representing _______ ordinary shares, no par value per share, of the Company (the “Ordinary Shares”) (“ADSs” shall mean the American Depositary Shares of the Company, each ADS representing _______ Ordinary Shares). The respective amounts of the Firm Shares to be purchased by each of the several Underwriters are set forth opposite their names on Schedule I hereto. In addition, the Company proposes to grant to the Underwriters an option to purchase up to an additional ___________ ADSs (the “Option Shares”) from the Company for the purpose of covering o
BI Contract No. 100704 CLINICAL SUPPLY AGREEMENTClinical Supply Agreement • February 5th, 2019 • Anchiano Therapeutics Ltd. • Pharmaceutical preparations • New York
WHEREAS, BioCancell’s Affiliated Company BioCancell Ltd. and BI RCV entered into a secrecy agreement (“CDA”) dated as of November 16, 2006, a material transfer agreement (“MTA”) dated as of April 3, 2013 and a Quality Agreement ("QA") dated as of September 12, 2013; and
